VIR: Koefisien rega marang pendapatan Vir Bio

Simbol lan logo merek Vir Biotechnology Inc (VIR)

The P/S trajectory illustrates the market valuation of Vir Biotechnology, Inc. (VIR), with the current level standing at 6.80. Vir Biotechnology, Inc. (VIR) develops antiviral drugs against influenza and hepatitis B through strategic alliances with scientific foundations. Production and testing are outsourced to third-party contractors. High liquidity enables the development of new platforms while protecting shareholder capital from dilution.

VIR: Kapitalisasi marang pendapatan vir.bio 04.07.2022 - 13.11.2026

Rincian analitis perusahaan Vir Bio (VIR)

- rega saiki lan proyeksi nilai saham:
Bagan rega vir.bio|VIR - Prakiraan konsensus analis
- informasi kapitalisasi pasar:
Kapitalisasi pasar Vir Bio|VIR - Nilai Total Perusahaan
- rincian nilai buku perusahaan:
Nilai Akuntansi Saham Vir Biotechnology|VIR - Aset Bersih Perusahaan|Nilai Pasar marang Nilai Buku vir.bio|VIR - Total Aset Perusahaan
- indikator beban kredit lan likuiditas emiten:
Utang marang Ekuitas Vir Biotechnology, Inc.|VIR - Utang jangka dawa marang modal|Koefisien utang jangka cendhak marang modal Vir Corp|VIR - Utang perusahaan|Utang-utang marang nilai buku Vir Bio|VIR - Kewajiban jangka dawa perusahaan|Gedhene kewajiban jangka cendhak Vir Biotechnology|Likuiditas darurat vir.bio
- informasi bathi lan kelipatan valuasi:
VIR - Bathi resik|Bathi mangsa ngarep Vir Biotechnology, Inc.|VIR - Pangali P/E|Pangali mangsa ngarep rega marang bathi Vir Biotechnology Inc|VIR - Rasio rega marang bathi tumrap wutah|Nilai perusahaan marang bathi operasional sadurunge panyusutan Vir Bio|VIR - Bathi sadurunge mbayar bunga, pajak, lan amortisasi|Bathi resik saben siji saham sajrone rolas wulan pungkasan Vir Biotechnology|VIR - Bathi saben saham sajrone rolas wulan pungkasan|Wutah bathi saben saham taun-ka-taun sajrone rolas wulan pungkasan vir.bio|VIR - Wutah bathi saben saham ing taun lumaku|Prakiraan wutah bathi resik saben saham ing taun ngarep Vir Biotechnology, Inc.
- indikator pendapatan dodolan lan penghasilan bisnis:
VIR - Pendapatan lan volume dodolan|Prakiraan dodolan perusahaan vir.bio|VIR - Kapitalisasi marang pendapatan|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep Vir Bio
Analisis fundamental perusahaan:VIR - vir.bio
Sampel barang Vir Biotechnology, Inc.

For Vir Biotechnology, Inc. (VIR), which is adapting its portfolio following a decline in demand for antivirals, the P/S ratio serves as an indicator of the market value of every dollar of revenue generated. Analyzing the price-to-sales ratio allows for an assessment of capitalization relative to actual sales, filtering out temporary noise and confirming business resilience driven by a strong scientific core and significant liquidity reserves.

Karo sapa Vir Biotechnology, Inc. saingan

Rasio rega marang pendapatan GILD (gilead.com)|Multiplikator P/S CDTX (Cidara Therapeutics Inc)|Koefisien rega marang pendapatan Novavax Inc (NVAX)|CVAC - Rasio rega marang pendapatan|Rasio kapitalisasi pasar marang pendapatan VALN (Valneva Vaccines)|SIGA (SIGA Technologies, Inc.) - Kapitalisasi marang pendapatan|emergentbiosolutions.com - Rasio kapitalisasi pasar marang pendapatan|AVIR (Atea Pharmaceuticals, Inc.) - Multiplikator P/S|Rasio rega marang pendapatan IVVD|Multiplikator P/S ENTA|Koefisien rega marang pendapatan Inovio Pharma|Rasio rega marang pendapatan HilleVax, Inc. HLVX|kalaristx.com (KLRS) - Rega marang dodolan|DYAI: Kapitalisasi marang pendapatan|NanoViricides, Inc. - Kapitalisasi marang volume dodolan|TLPH: Multiplikator P/S|Rega marang dodolan Cocrystal Pharma Corp (COCP)|TRAW (Traws Pharma Inc) - Multiplikator P/S|Kapitalisasi marang pendapatan Virios Therapeutics (DWTX)|Multiplikator P/S QLGN|ALVR (allovir.com) - Rasio kapitalisasi pasar marang pendapatan|Rasio rega marang pendapatan VBI Vaccines VBIV|VIRI: Rasio kapitalisasi marang pendapatan|VXRT - Rasio rega marang pendapatan